Imfinzi 500mg Injection

Imfinzi 500mg injection is an anticancer medication classified as an Anti-PD-1 monoclonal antibody, with Durvalumab as its active ingredient.
It is indicated for the treatment of non-small cell lung cancer (which has not metastasized beyond the chest), small cell lung cancer (which has spread within the lungs), and biliary tract cancers (cancers affecting the bile ducts).
Before receiving this injection, inform your doctor if you have a history of organ transplants, liver issues, lung or respiratory problems, or autoimmune diseases (conditions where the immune system attacks the body’s own cells).

Common side effects associated with this injection include cough, upper respiratory infections, fatigue, shortness of breath, lung inflammation, and rashes.
This medication may elevate the risk of immune-mediated adverse reactions such as pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis, which have been documented.

This medication is not advised for individuals under 18 years of age.
During treatment with Imfinzi 500mg injection, your healthcare provider may regularly check your white blood cell counts, platelets, blood sugar levels, electrolytes, and kidney function to avert serious complications.
This drug is frequently used in conjunction with carboplatin or cisplatin for small-cell lung cancer treatment and is also combined with gemcitabine for biliary tract cancer therapy.
It is important to note that this medication may lead to kidney issues.
Notify your doctor if you have been diagnosed with kidney disorders, heart failure, elevated blood cholesterol, or hypertension prior to commencing this treatment.